QAD Inc. (NASDAQ: QADB) said that Aesica Pharmaceuticals S.r.l. has upgraded to QAD Enterprise Applications Enterprise Edition.
The upgrade helped Aesica meet the deadline for a new serialization regulation for the Chinese market. A recently published case study shares the complete details of the implementation and its benefits.
Aesica is a leading pharmaceutical contract development and manufacturing organization (CDMO). The company, operating in a highly regulated industry, had to meet product serialization and tracking regulations to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process and minimizing financial loss.
Aesica Pharmaceuticals S.r.l. supplies contract development and contract manufacturing services for finished dose and active pharmaceutical ingredients to the world´s leading pharmaceutical companies and emerging biotechnology organizations. For additional information go to www.aesica-pharma.co.uk.
QAD is a provider of enterprise software and services designed for global manufacturing companies. Its website is at www.qad.com.